Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 11/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23084859 | 0.94 | CYP1A2 (0.42) | CYP1A2EPHX1SIGMAR1EPHX2MEN1 | |
| SCHEMBL8451118 | 0.88 | EPHX1 (0.37) | CYP1A2EPHX1SIGMAR1EPHX2KDM4E | |
| SCHEMBL22001216 | 0.85 | EPHX1 (0.34) | CYP1A2EPHX1SIGMAR1EPHX2MEN1 | |
| SCHEMBL19173905 | 0.83 | GNAI3 (0.36) | CYP1A2EPHX1MEN1KMT2AALDH1A1 | |
| SCHEMBL21166219 | 0.81 | — | — | |
| SCHEMBL21790799 | 0.79 | CNR2 (0.45) | EPHX1 | |
| SCHEMBL6062189 | 0.79 | POLB (0.41) | CYP1A2EPHX1SIGMAR1EPHX2KDM4E | |
| SCHEMBL7776718 | 0.79 | POLB (0.41) | CYP1A2EPHX1SIGMAR1EPHX2KDM4E | |
| SCHEMBL8967535 | 0.78 | CYP1A2 (0.42) | CYP1A2EPHX1SIGMAR1EPHX2MEN1 | |
| SCHEMBL13741870 | 0.78 | DRD2 (0.33) | CYP1A2EPHX1KMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
| US-9732083-B2 | Tricyclic gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | KCNJ11, KCNJ2, KCNJ1 | CYP1A2 1148/4885EPHX1 2639/4885SIGMAR1 1660/4885 |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | CYP1A2 1148/4885EPHX1 2639/4885SIGMAR1 1660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.